Article Sidebar

PDF
Date Published: 08/06/2021
Abstract Views: 298
Views PDF: 227
DOI: https://doi.org/10.51298/vmj.v500i1.326
Issue
Vol. 500 No. 1 (2021)
Section
Các bài báo
How to Cite
Xuân Thủy, T. ., & Thị Thu Hương, Đinh . (2021). THE BLEEDING RATE, THE MEDICINE STOPED RATE AND THE EFFECT ON SOME BIOCHEMICAL BLOOD PARAMETERS OF TICAGRELOR IN COMPARE TO CLOPIDOGREL ON THE PATIENTS WITH LOWER EXTREMITY ARTERY DISEASE. Vietnam Medical Journal, 500(1). https://doi.org/10.51298/vmj.v500i1.326

THE BLEEDING RATE, THE MEDICINE STOPED RATE AND THE EFFECT ON SOME BIOCHEMICAL BLOOD PARAMETERS OF TICAGRELOR IN COMPARE TO CLOPIDOGREL ON THE PATIENTS WITH LOWER EXTREMITY ARTERY DISEASE

Trần Xuân Thủy, Đinh Thị Thu Hương

Main Article Content

Abstract

Background: Ticagrelor is an antiplatelet drug through reversible inhibition of the P2Y12 receptor. This drug do not have to metabolize by the live like clopidogel.  On the patients with acute coronary syndrom in PLATO trial, ticagrelor is not only superior to clopidogrel in reduction of cardiovascular events, but it also does not increase the bleeding risks. So, we conducted this trial on the patient with lower extremity artery disease (PAD) to compare the bleeding risk, the medicine stoped rate and effect on some biochemical blood parameters of ticagrelor with clopidogrel. Subjects and Methods: In this clinical trial, we randomly assigned 178 patients with  PAD to receive monotherapy with ticagrelor (90mg twice daily) or clopidogrel (75mg once daily). The end points were the bleeding rate, the cerebral hemorrhage rate, the medicine stoped rate, and concentration of some biochemical blood parameters. The time of follow-up was 18-36 months. Results: The bleeding rate in ticagrelor group was 7,8%  v.s 6,8% in clopidogrel group with p = 0,79. The major bleeding rate in two group was similar (1,1%; in ticagrelor group v.s 2,3% in clopidogrel group), with p = 0,546. There was one cerebral hemorrhage event in clopidogrel group. We did not meet any death beacause of bleeding event in two groups. The medicine stoped rate in ticagrelor group was 12,4% v.s 17% in clopidogrel group, with OR(CI95%) = 1,46 (0,63 – 3,38). Concentration of some biochemical blood parameters: creatinin, GOT, GPT, Bilirubin, glucose and heamoglobin were equal in both groups. Conclusion: The bleeding risk, the medicine stoped rate and effect on some biochemical blood parameters of ticagrelor and  clopidogrel were equal in the patient with lower extremity artery disease.


 

Article Details

Keywords

ticagrelor, clopidogrel

References

1. Hiatt W.R, Goldstone J, Smith S et al (2008). Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation, 118(25), 2826-9.
2. Pande R. L, Perlstein T. S, Beckman A et al (2011). Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation, 124(1), 17-23.
3. Hirsch A. T, Criqui M. H et al (2001). Peripheral arterial disease detection, awareness, and treatment in primary care. Jama, 286(11), 1317-24.
4. Mega J.L, Simon T, Collet J.P et al (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: ametaanalysis. JAMA, 304(16), 1821–1830.
5. Teng R, Oliver S, Hayes MA, Butler K (2010). Absorption, distribution, metabolism and excretion of ticagrelor in healthy subjects. Drug Metab Dispos, 38,1514–21.
6. Wallentin L, Becker R.C et al (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361(11), 1045-57.